12:00 AM
Dec 15, 2003
 |  BioCentury  |  Strategy

Qiagen: 'Never deviate'

More than any other German biotech company, Qiagen N.V. was proof to the outside world that a biotech sector had emerged in Germany. Yet no other company has been able to duplicate its success. And given the difficulties encountered by the plethora of service companies in that nation, it may also be ironic that the most successful life science start-up in Germany is a supply company.

Qiagen (FSE:QIA; QGENF, Venlo, the Netherlands) announced a changing of the guard last month, as CEO and co-founder Metin Colpan stepped down to be replaced by long-time CFO Peer Schatz.

Schatz has no plans to change a formula that works. QIA is determined to stay what it is: a company supplying technologies and products for separating and purifying nucleic acids.

"For Qiagen's success," Colpan said, "the most important points have been to decide to develop and supply products for nucleic acid purification, to market the products on their own, and to never deviate from this focus."

For 2002, QIA reported sales of $299 million. The company has more than 1,500 employees in 10 countries, with a sales force of about 500 people in 9 countries, plus a network of...

Read the full 966 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >